Shanghai Raising Pharmaceutical Co. Ltd. has synthesized prodrugs of thiamine acting as amyloid-β (Aβ) protein production inhibitors reported to be useful for the treatment of neurodegenerative diseases, preferably Alzheimer's disease (AD).

Research shows that microglia, macrophage cells found in the central nervous system, are needed to maintain nerve health by preventing the degeneration of the myelin sheath that protects neurons. The study, led by the University of Edinburgh and the University of Toronto and published on Dec. 14, 2022, in Nature, showed microglia could be a potential therapeutic target for neurological conditions involving myelin degeneration.

Alkermes Controlled Therapeutics Inc. has patented orexin OX2 receptor (OX2R) agonists reported to be useful for the treatment of cataplexy.

Investigators from Cerevance Inc. have reported the discovery and preclinical characterization of a novel tandem pore domain halothane-inhibited K+ channel 1 (THIK-1) inhibitor, C-101248, being developed for the treatment of neuroinflammation in Alzheimer’s disease (AD). NETSseq and histological analysis revealed that THIK-1 expression was up-regulated in microglia from different cortical regions of AD donors compared with aged matched nondemented control brains.

Sun Yat-Sen University has divulged pyrimidodiazepanone compounds reported to be useful for the treatment of depression.

Tuberous sclerosis complex (TSC) is a multisystemic disorder caused by loss-of-function mutations in the TSC1 or TSC2 genes. Its clinical phenotype is heterogenous, but most patients with TSC have epilepsy.